Get the Stockscreener App
200.68
0.03%
0.07
Pre-market:
199.46
-1.22
-0.61%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Cardinal Health Inc stock is traded at $200.68, with a volume of 1.54M.
It is up +0.03% in the last 24 hours and up +0.06% over the past month.
Cardinal Health is one of three leading pharmaceutical wholesalers in the US, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. Cardinal, Cencora, and McKesson hold well over 90% of the US pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
See More
Previous Close:
$200.61
Open:
$201.98
24h Volume:
1.54M
Relative Volume:
0.80
Market Cap:
$47.00B
Revenue:
$250.74B
Net Income/Loss:
$1.55B
P/E Ratio:
30.69
EPS:
6.5398
Net Cash Flow:
$4.39B
1W Performance:
+2.81%
1M Performance:
+0.06%
6M Performance:
-4.20%
1Y Performance:
+31.60%
1-Day Range:
$199.69
$202.77
1-Week Range:
$195.32
$203.98
52-Week Range:
$137.75
$233.60
Cardinal Health Inc Stock (CAH) Company Profile
Name
Cardinal Health Inc
Sector
Industry
Phone
(614) 757-3033
Address
7000 CARDINAL PLACE, DUBLIN, OH
Compare CAH vs MCK, COR, HSIC, AHG
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAH
Cardinal Health Inc
|
200.68 | 46.98B | 250.74B | 1.55B | 4.39B | 6.5398 |
MCK
Mckesson Corp
|
766.08 | 92.14B | 403.43B | 5.10B | 5.41B | 38.47 |
COR
Cencora Inc
|
274.91 | 51.64B | 328.68B | 2.55B | 1.56B | 13.03 |
HSIC
Henry Schein Inc
|
74.21 | 8.37B | 13.18B | 419.00M | 521.00M | 3.2704 |
AHG
Akso Health Group Adr
|
1.53 | 1.29B | 14.85M | -136.07M | 7.25M | -0.4726 |
Cardinal Health Inc Stock (CAH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Upgrade | Citigroup | Neutral → Buy |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Jun-03-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-05-25 | Upgrade | Jefferies | Hold → Buy |
| Jan-08-25 | Upgrade | TD Cowen | Hold → Buy |
| Jan-07-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-06-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-13-24 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-04-24 | Resumed | Mizuho | Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Feb-09-24 | Upgrade | Argus | Hold → Buy |
| Jan-03-24 | Initiated | Barclays | Overweight |
| Dec-14-23 | Initiated | Wells Fargo | Underweight |
| Jul-10-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-31-23 | Initiated | Citigroup | Neutral |
| Feb-03-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-04-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-22-22 | Resumed | Morgan Stanley | Overweight |
| May-26-22 | Downgrade | Barclays | Overweight → Equal Weight |
| May-18-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-12-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-01-22 | Resumed | Credit Suisse | Neutral |
| Aug-06-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-05-21 | Downgrade | BofA Securities | Buy → Underperform |
| May-10-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-21 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Nov-02-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-25-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Jul-20-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-15-20 | Upgrade | UBS | Neutral → Buy |
| Apr-23-20 | Resumed | Credit Suisse | Neutral |
| Mar-20-20 | Upgrade | BofA/Merrill | Underperform → Buy |
| Feb-12-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-07-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-16-19 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-12-19 | Initiated | Deutsche Bank | Hold |
| Aug-27-19 | Downgrade | Argus | Buy → Hold |
| Aug-20-19 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-18-19 | Initiated | Guggenheim | Neutral |
| Jan-17-19 | Initiated | UBS | Neutral |
| Nov-16-18 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Apr-24-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Apr-02-18 | Upgrade | Argus | Hold → Buy |
| Mar-08-18 | Initiated | Barclays | Equal Weight |
| Feb-27-18 | Resumed | BofA/Merrill | Underperform |
| Jan-05-18 | Initiated | Evercore ISI | In-line |
View All
Cardinal Health Inc Stock (CAH) Latest News
Cardinal Health Inc. stock (US14149Y1082): Analyst target cut meets steady dividend story - AD HOC NEWS
Cardinal Health, Inc. (CAH) Stock Analysis: Unveiling a 22% Upside Potential in the Healthcare Sector - DirectorsTalk Interviews
CAH Stock Price, Quote & Chart | CARDINAL HEALTH INC (NYSE:CAH) - ChartMill
Cardinal Health Inc. stock (US14149Y1082): Dividend move and healthcare distribution in focus - AD HOC NEWS
Spotting Winners: Cardinal Health (NYSE:CAH) And Healthcare Providers & Services Stocks In Q1 - Yahoo Finance
Precision Trading with Cardinal Health Inc. (CAH) Risk Zones - Stock Traders Daily
Cardinal Health stock (US14149Y1082): focus on cost cuts and pharma growth after latest quarterly re - AD HOC NEWS
Here's Why You Should Add Cardinal Health Stock to Your Portfolio Now - Yahoo Finance
Possible Bearish Signals With Cardinal Health Insiders Disposing Stock - Yahoo Finance
Cardinal Health (CAH) Stock Price, News & Analysis $CAH - MarketBeat
Cardinal Health Inc. stock (US14149Y1082): shares react to Q3 2026 earnings beat - AD HOC NEWS
Cardinal Health Inc. stock (US14149Y1082): steady gains and healthcare exposure for US investors - AD HOC NEWS
Is CAH Becoming the Backbone of US Healthcare Infrastructure? - TradingView
Cardinal Health (CAH) is a Top-Ranked Value Stock: Should You Buy? - Eastern Progress
Which Is a Better Investment, BrightSpring Health Services, Inc. or Cardinal Health, Inc. Stock? - AAII
Daily Brief Health Care: Dermavon Holdings, Alebund Pharmaceuticals Jiangsu, Alnylam Pharmaceuticals, Artrya , Bavarian Nordic A/S, Cardinal Health, Dexcom Inc, American Shared Hospital Servi, Eli Lilly & Co, Abeona Therapeutics and more - Smartkarma
Cardinal Health stock (US14149Y1082): dividend hike and higher FY2026 outlook - AD HOC NEWS
Cardinal Health Inc. stock outperforms competitors on strong trading day - MarketWatch
Top Companies Driving Innovation In Specimen Bag Zip Closure Solutions - SNS Insider
CAH Technical Analysis | Trend, Signals & Chart Patterns | CARDINAL HEALTH INC (NYSE:CAH) - ChartMill
Cardinal Health Inc. stock (US14149Y1082): dividend hike and higher FY2026 guidance in focus - AD HOC NEWS
Cardinal Health dividend preview: strong Q3 earnings point to May payout boost - MSN
Why is Cardinal Health stock sinking Thursday? - MSN
Cardinal Health (CAH) Is Up 6.3% After Raising 2026 EPS Outlook and Trimming Tax Guidance - Sahm
Cardinal Health Is One of the S&P 500’s Biggest Decliners Today. A Guidance Hike Didn’t Matter. - Barron's
Does Cardinal Health's (CAH) Higher Dividend and Guidance Hint at a New Capital Allocation Play? - Yahoo Finance
Cardinal Health Inc. stock (US14149Y1082): EPS beat contrasts with recent share-price weakness - AD HOC NEWS
Do options traders know something about Cardinal Health stock we don't? - MSN
Cardinal Health Inc. stock (US14149Y1082): earnings beat meets fresh momentum signal - AD HOC NEWS
Cardinal Health Inc (CAH) Stock Up 4.3% but GF Value Says Overva - GuruFocus
CAH Stock Down Nearly 9.4% YTD: Should You Buy, Hold or Sell? - TradingView
Cardinal Health stock (US14149Y1082): Beats Q3 Earnings, Analysts Trim Price Targets - AD HOC NEWS
Cardinal Health Was Supposed to Beat UnitedHealth. Did It? Will It? - Yahoo Finance
BofA Securities Maintains Cardinal Health(CAH.US) With Buy Rating, Maintains Target Price $240 - Moomoo
Baird Keeps Outperform on Cardinal Health (CAH) Following Earnings Update - Insider Monkey
Cardinal Health Inc stock (US14149Y1082): Recent earnings beat highlights strong performance - AD HOC NEWS
Transcript : Cardinal Health, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 08 - marketscreener.com
Can CAH Sustain Growth on Booming Pharmaceutical & Specialty Segment? - TradingView
Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH) and Dexcom (DXCM) - The Globe and Mail
Should Value Investors Buy Cardinal Health (CAH) Stock? - Yahoo Finance
Cardinal Health Extends Beyond Distribution With Surgical Case Cart Automation - Yahoo Finance
Cardinal Health's (NYSE:CAH) Earnings Offer More Than Meets The Eye - Moomoo
We Think Cardinal Health's (NYSE:CAH) Solid Earnings Are Understated - Yahoo Finance
Cardinal Health stock (US14149Y1082): Q4 revenue beats estimates by 1.2% - AD HOC NEWS
Cardinal Health, Inc. (CAH) Stock Analysis: Strong Buy Ratings and 33.55% Potential Upside Propel Investor Interest - DirectorsTalk Interviews
Is It Time To Reassess Cardinal Health (CAH) After Its Multi Year Share Price Surge - Sahm
Liberty One Defensive Dividend Growth ETF 's Cardinal Health Inc(CAH) Holding History - GuruFocus
Here's why you should add Cardinal Health stock to your portfolio now - MSN
Here's Why Cardinal Health (CAH) is a Strong Value Stock - Yahoo Finance
What Are Wall Street Analysts' Target Price for Cardinal Health Stock? - Barchart.com
Pregnancy Detection Kits Market Analysis Report 2026 - GlobeNewswire Inc.
Cardinal Health Inc Stock (CAH) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.57%
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):